CTX-M-35 extended-spectrum beta-lactamase conferring ceftazidime resistance in Citrobacter koseri.
CTX-M-35 extended-spectrum beta-lactamase conferring ceftazidime resistance in Citrobacter koseri.
复制标题
CTX-M-35 超广谱 β-内酰胺酶赋予科塞里柠檬酸杆菌头孢他啶耐药性。
DOI:
10.1016/j.ijantimicag.2009.12.004
复制
发表时间:
2010
影响因子:
10.8
通讯作者:
Doi,Yohei
中科院分区:
文献类型:
--
作者:
Tian,Guo-Bao;Adams-Haduch,JenniferM;Qureshi,ZubairA;Wang,Hong-Ning;Doi,Yohei
CTX-M-type extended-spectrum β-lactamases (ESBLs) are a group of ESBLs that are becoming increasingly common worldwide. Over 90 CTX-M-type enzymes have been registered (http://www. lahey. org/studies), belonging to five clusters based on amino acid sequence homology. Unlike TEM-and SHV-type ESBLs, most CTX-M-type ESBLs have strong substrate preference for cefotaxime over ceftazidime. Here we report identification of a CTX-M-2 variant that preferentially hydrolyses ceftazidime, obtained from a clinical isolate in the USA.The patient was a 98-year-old female who was admitted to the University of Pittsburgh Medical Center (Pittsburgh, PA) for exacerbation of congestive heart failure. She had not received any antimicrobials since her admission. During the hospital course she developed symptoms of cystitis, and urine taken on the seventh hospital day contained≥ 182 leukocytes/high power field. Concurrent urine culture grew≥ 105 colony-forming units (CFU)/mL of Citrobacter koseri and Escherichia coli. After 6 days of treatment with intravenous and then oral cefuroxime, to which E. coli but not C. koseri was susceptible, the patient became asymptomatic and leukocytes cleared from the urine. Repeat urine culture grew 80 000 CFU/mL of C. koseri. This was felt to represent colonisation and the patient was not further treated with antimicrobial therapy.